Last Updated 15 December 2014
Tumor necrosis factor (TNF)-α inhibitors continue to dominate the multibillion-dollar rheumatoid arthritis (RA) market. An increase in the prevalent RA population, emphasis on early diagnosis and early initiation of disease-modifying antirheumatic drug (DMARD) treatment, and the need for therapies with better efficacy and safety profiles will continue to drive the growth of the RA market. Clear market opportunities exist for alternative biologics and oral compounds, especially in the population of patients refractory to TNF-α inhibitor therapy. The recently approved oral Jak inhibitor tofacitinib (Pfizer/Takeda’s Xeljanz) and other emerging agents in late clinical development have the potential to make a substantial impact on the current treatment algorithm for RA.